Lexicon Pharmaceuticals | LXRX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Abbott USD 2.39B 27M 2026-03
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
AstraZeneca USD 3.91B 1.28B 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Illumina USD 157M 220M 2026-03
Insmed USD -326.93M 41.77M 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
J&J USD 7.82B 2.86B 2026-03
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
MacroGenics USD -14.93M 31.75M 2025-12
MannKind USD -20.93M 28.71M 2025-12
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Novartis USD 3.84B 802M 2026-03
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Thermo Fisher Scientific USD 2.12B 295M 2025-12
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12